Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Newer Rheumatoid Arthritis Drugs: Harmful On The Liver?

27.10.2003


Results of 41,885 Patient Analysis Announced at the American College of Rheumatology Annual Scientific Meeting



The disease modifying anti-rheumatic arthritis drug (DMARD), leflunomide does not have a higher risk of liver side effects than the traditional drug, but other newer DMARDs may, according to investigators at the Research Institute of the McGill University Health Center (MUHC). Their findings, presented today at the American College of Rheumatology Annual Scientific Meeting, show that this drug, leflunomide, has a similar effect on the liver as the traditional drug, methotrexate, and that newer biologic DMARDs may have greater risks.

“We decided to look specifically at the effect of leflunomide on the liver because of recent spontaneous reports with this drug,” said MUHC Director of Clinical Epidemiology Dr. Samy Suissa and lead investigator of the study. “We found that patients taking leflunomide had the same risk of hepatic events than patients taking methotrexate.”
Rheumatoid arthritis, a chronic inflammatory disease of joints and other internal organs, affects one out of 100 Canadians, and affects two million Americans. It leads to swelling, pain, stiffness, and possible loss of function and deformity of these joints. Treatments for rheumatoid arthritis are increasingly effective in slowing down this debilitating disease but their side effects can cause other health problems.


Dr. Suissa, also a professor at McGill University, and colleagues looked at data obtained from two large American health insurance companies that included 41,885 DMARD users. The DMARDs dispensed included leflunomide, the newer biologic DMARDs, methotrexate and other traditional DMARDs. Their study shows that the risk of serious hepatic events was significantly increased only with biological modifier DMARDs, not with leflunomide or other DMARDs.

“Evaluative studies such as these are extremely important in determining the best treatment options for patients while avoiding harm,” said Suissa. “Our findings suggest the hepatic side effects observed with the biologic DMARDs must be investigated further.”

The study was supported by Aventis, the makers of leflunomide.

For more information, please contact:
Christine Zeindler, MSc
Communications Coordinator (Research)
McGill University Health Centre Communications Services
www.muhc.ca
(514) 934-1934 ext. 36419
pager: (514) 406-1577

Leslie Anderson
onsite contact
mobile 917-370-6924

Christine Zeindler | MUHC
Further information:
http://www.muhc.ca

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>